Powered by
Mojo Pet Supplements VHP Hemp (Cannabis sativa):
Clinical rationale, safety and integrative use in animal health
Hemp-derived veterinary health products (VHPs) have emerged as regulated, low-risk adjuncts in integrative veterinary medicine. Mojo Pet Supplements VHP Hemp (Cannabis sativa) Tablet Chews are a Health Canada–listed Veterinary Health Product science formulated to support physiologic homeostasis in dogs and cats through endocannabinoid system (ECS) modulation, medicinal compounds and nutritional omega fatty acid support, and immune balance. This article reviews the formulation, mechanism of action, safety profile, and evidence-aligned clinical applications of Mojo Pet Supplements VHP Hemp Tablet Chews, providing veterinarians and registered veterinary technicians with a practical framework for responsible clinical integration.
A complementary wellness tool in veterinary practice
The role of hemp nutraceuticals and veterinary health products in companion animal medicine has expanded significantly as veterinarians seek safe, compliant tools to support wellness, aging, mobility, stress resilience, and chronic care.
Hemp (Cannabis sativa)–derived products, when properly regulated and formulated, offer low-dose phytochemical support without psychoactive effects.
Mojo Pet Supplements VHP Hemp Tablet Chews are listed with Health Canada’s Veterinary Drug Directorate (VDD) as a Veterinary Health Product (VHP). As such, they are intended to support normal physiological function rather than diagnose, treat, or cure disease.
Regulatory classification and product overview
Mojo VHP products meet all of Health Canada’s regulatory requirements for low‑risk Veterinary Health Products (VHPs), including the use of safe ingredients, documented evidence of safety, transparent labeling, and mandatory post‑market monitoring. The THC content is maintained at ≤ 10 ppm, ensuring non-psychoactive use in companion animals.
From a manufacturing standpoint, production occurs in SQF Level 3–certified facilities that operate in alignment with Good Manufacturing Practices (GMP). This ensures consistent formulation, strict lot‑to‑lot traceability, and the use of high‑quality, human‑grade ingredients throughout the process.
Formulation overview
Full-Spectrum Crude Hemp (Cannabis sativa) Oil/Protein provides a naturally occurring matrix of compounds, phytocannabinoids, terpenes, flavonoids, and omega fatty acids and all-natural nutrition within a low-dose VHP range.
This formulation is not an isolated high-dose CBD product and does not aim to produce pharmacologic sedation or intoxication.
Active ingredients:
- 830 mg of 100% Pure Hemp (Cannabis Sativa) Oil (per supplement)
- 1,3 g of 100% Pure Hemp (Cannabis Sativa) Dried (per supplement)
Inactive ingredients:
- Beef liver, chicken, salmon, and duck enhance palatability and contribute essential nutrients.
- Cellulose fibers support intestinal motility and stool quality.
-
Oat bran, glycerin, and guar gum contribute to texture, binding, and overall chew stability.
These functional excipients ensure excellent daily acceptance and ease of administration in both dogs and cats.
Mechanism of action: endocannabinoid system (ECS)
the ECS is a conserved neuromodulatory and immunoregulatory system present in all mammals, including dogs and cats, playing a role in homeostasis across multiple organ systems.
CB1 receptors, located throughout the central and peripheral nervous systems, play a key role in modulating stress responses, anxiety, and nociception. CB2 receptors, located throughout immune cells and peripheral tissues, help regulate inflammatory cytokines and immune balance.
Low-dose, full-spectrum hemp compounds interact indirectly with ECS signaling, supporting:
- Reduced inflammation
- Improved stress resilience
- Balanced immune function
Evidence‑based clinical indications
|
Category
|
Indications/Ideal patients
|
Mechanisms/Clinical rationale
|
Clinical benefits
|
|
Inflammation and joint health support
|
|
|
|
|
Anxiety, stress and behavioral support
|
|
|
|
|
Mobility and senior wellness
|
|
|
|
|
Skin, coat and allergy support
|
|
|
|
|
Cognitive aging and neurological support
|
|
|
|
Safety and precautions
Mojo VHP products demonstrate a strong safety profile:
- Non‑psychoactive (THC ≤ 10 ppm)
- Suitable for long‑term daily use
- Free from artificial colors and flavors
Adverse effects reported are rare and generally mild, including occasional soft stools or transient changes in appetite. Caution is advised when using the product in pregnant or lactating animals, in patients with hepatic disease, and in those receiving medications with a narrow therapeutic index that are metabolized by the liver.
Mojo VHP Hemp Chewable Tablets offer a palatable, regulated, and scientifically grounded option to support the overall well‑being of dogs and cats. Their low‑risk profile, precise dosing format, and gentle physiological action make them a valuable tool in modern integrative veterinary care, particularly for supporting mobility, stress resilience, senior vitality, skin health, and cognitive wellness.
Disvover Mojo Pet Supplements for cats and dogs
You must be logged in to access the page.
References:
- Kogan LR, Hellyer PW, Robinson NG. Consumers’ perceptions of hemp products for animals. J Am Holist Vet Med Assoc. 2017;42:40-48.
- Brutlag A, Hommerding H. Toxicology of marijuana, synthetic cannabinoids, and cannabidiol in dogs and cats. Vet Clin Small Anim. 2018;48:1087–1102.
- Bergamaschi, MM, Costa-Querioz RH, Crippa JAS, Zuardi AW. Safety and side effects of cannabidiol, a Cannabis sativa constituent. Curr Drug Saf. 2011; 6(4):237–249.
- Landa L, Sulcova A, Gbelec P. The use of cannabinoids in animals and therapeutic implications for veterinary medicine: A review. Vet Med. 2016; 61(3):111–122.
- McGrath S, Bartner LR, Rao S, PackerRA, Gustafson DL. Randomized blinded controlled clinical trial to assess the effect of oral cannabidiol administration in addition to conventional antiepileptic treatment on seizure frequency in dogs with intractable idiopathic epilepsy. J Am Vet Med Assoc 2019;254(11): 1301–1308.
- McGrath S, Bartner LR, Rao S, Kogan LR, Hellyer PW. A report of adverse effects associated with the administration of cannabidiol in healthy dogs. J Am Holist Vet Med Assoc. 2018;52:34–38.
- Deabold KA, Schwark WS, Wolf L, Wakshlag JJ. Single-dose pharmacokinetics and preliminary safety assessment with use of CBD-rich hemp nutraceutical in healthy dogs and cats. Animals. 2019;9(832): doi: 10.3390/ani9100832.
- Bartner LR, McGrath S, Rao S, Hyatt LK, Wittenburg LA.Pharmacokinetics of cannabidiol administered by 3 delivery methods at 2 different dosages to healthy dogs. Can J Vet Res. 2018;82(3):178–183.
- Gamble LJ, Boesch JM, Frye CW, Schwark WS, et al. Pharmacokinetics, safety, and clinical efficacy of cannabidiol treatment in osteoarthritic dogs. Front Vet Sci. 2018;5:165– 172.